J
Jaromír Švestka
Researcher at Masaryk University
Publications - 76
Citations - 673
Jaromír Švestka is an academic researcher from Masaryk University. The author has contributed to research in topics: Perphenazine & Citalopram. The author has an hindex of 11, co-authored 76 publications receiving 632 citations.
Papers
More filters
Journal ArticleDOI
Fighting stigma of mental illness in midsize European countries
Alina Beldie,Johan A den Boer,Cecilia Brain,Eric Constant,Maria Luísa Figueira,Igor Filipčić,B. Gillain,Miro Jakovljević,Marek Jarema,Daniela Jelenova,Oğuz Karamustafalıoğlu,Blanka Kores Plesnicar,Andrea Kovacsova,Klara Latalova,Josef Marksteiner,Filipa Palha,Jan Pecenak,Jan Prasko,Dan Prelipceanu,Petter Andreas Ringen,Norman Sartorius,Erich Seifritz,Jaromír Švestka,Magdalena Tyszkowska,Johannes Wancata +24 more
TL;DR: Although much has been done against the stigmatization and discrimination of the mentally ill, fighting stigma remains an essential task for mental health programs and for society.
Journal ArticleDOI
Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence
Norman Sartorius,Thomas C. Baghai,David S. Baldwin,Barbara Barrett,Ursula Brand,W. Wolfgang Fleischhacker,Guy M. Goodwin,Heinz Grunze,Heinz Grunze,Martin Knapp,Brian E. Leonard,Jeffrey A. Lieberman,Yoshibumi Nakane,Roger M. Pinder,Alan F. Schatzberg,Jaromír Švestka,Pierre Baumann,Kareem Ghalib,John C. Markowitz,Frank Padberg,Max Fink,Toshiaki A. Furukawa,Konstantinos N. Fountoulakis,Peter Jensen,Shigenobu Kanba,Anita Riecher-Rössler +25 more
TL;DR: The Task Force on Antidepressant Medications was established to examine all aspects of therapy with antidepressant drugs and to provide mental health and other professionals with comprehensive and objective information about the different aspects of the use of antidepressants important in clinical practice.
Journal ArticleDOI
Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses.
Eva Češková,Jaromír Švestka +1 more
TL;DR: Risperidone had the benefit of a lower incidence of extrapyramidal side-effects and no statistically significant difference was found between the groups in any of the factors or items except guilt feeling, anxiety, and factor I--anxiety/depression--(p < 0.02) in favour of haloperidol.
Journal Article
Treatment of acute agitation in psychotic disorders
TL;DR: Evidence suggests that second-generation antipsychotics should be among the first-line choices in the treatment of agitation in acute psychosis.
Journal ArticleDOI
Escitalopram for the treatment of major depression and anxiety disorders.
Cyril Höschl,Jaromír Švestka +1 more
TL;DR: Compared with other antidepressants, escitalopram is generally better tolerated, its onset of action is relatively fast, and its use may have cost–effectiveness and cost–utility advantages.